Shopping Cart
- Remove All
 
Your shopping cart is currently empty
BPR1K871, a preclinical development candidate for anti-cancer therapy [1], is a potent, selective dual inhibitor targeting FLT3 and AURKA, with IC50 values of 19 nM and 22 nM, respectively.

| Pack Size | Price | Availability | Quantity | 
|---|---|---|---|
| 10 mg | $1,240 | 7-10 days | |
| 25 mg | $2,130 | 7-10 days | 
| Description | BPR1K871, a preclinical development candidate for anti-cancer therapy [1], is a potent, selective dual inhibitor targeting FLT3 and AURKA, with IC50 values of 19 nM and 22 nM, respectively.  | 
| Targets&IC50 |  FLT3:19 nM , AURKA:22 nM   | 
| In vitro | BPR1K871 demonstrates strong anti-proliferative effects on MOLM-13 and MV4-11 AML cells, achieving an EC50 of approximately 5 nM [1].  | 
| In vivo | BPR1K871, a multi-kinase inhibitor, is utilized for the treatment of acute myeloid leukemia (AML) and solid tumors [1].  | 
| Synonyms | DBPR114 | 
| Molecular Weight | 526.05 | 
| Formula | C25H28ClN7O2S | 
| Cas No. | 2443767-35-7 | 
| Relative Density. | 1.387 g/cm3 (Predicted) | 
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 125 mg/mL (237.62 mM), Sonication is recommended.   | |||||||||||||||||||||||||||||||||||
Solution Preparation Table  | ||||||||||||||||||||||||||||||||||||
DMSO 
  | ||||||||||||||||||||||||||||||||||||

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.